7:20 am Morning Networking Coffee
8:20 am Chairperson’s Opening Remarks
Driving the Vision & Success of Next Generation mRNA-Based Vaccines for Infectious Diseases
8:30 am mRNA Vaccines for a Pandemic Response
Synopsis
- Introduce prototype pandemic pathogen framework
- Zika vaccine development as model prototype pathogen
9:00 am Sa-mRNA Influenza Vaccines Provide Multiple Potential Layers of Protection Against Influenza
Synopsis
- Influenza is a complicated virus with multiple co-circulating and evolving strains which makes for a challenging vaccine target
- Sa-mRNA vaccines can generate robust B-cell and T-cell responses
- Robust CD8+ T-cell responses add another layer of protection over the more standard antibody responses that generate protection with current vaccines
9:30 am Next Generation Technologies for Broad Application of mRNA Vaccines
Synopsis
- Lessons learned from COVID-19
- Addressing key limitations of current mRNA vaccines
- Potential for application beyond preventive vaccines
10:00 am Boost Your Vaccine Manufacturing: Accelerating for a Rapid Response
Synopsis
- The clinical promise of mRNA therapeutics and vaccines is clear, but their novelty also brings new challenges to the
manufacturing process - Strategies and technologies for advancing and accelerating vaccine manufacturing
- How to address the challenges of developing a robust, optimized, scalable, and integrated mRNA manufacturing process
10:30 am Morning Networking Break
12:30 pm Networking Lunch Break
3:00 pm Afternoon Networking Break
Achieving a Successful Route to Equitable Distribution for mRNA-Based Therapeutics & Vaccines
3:30 pm Building mRNA Vaccine Capacity in LMICs
Synopsis
- Pandemic has highlighted inequity in terms of access between regions with vaccine manufacturing capacities and region with none. Following COVID-19 massive demands from LMICs for access to mRNA technology know-how and manufacturing capacity has raised
- Multiple initiatives are underway to transfer mRNA technology to LMICs challenging with sustainability of infrastructures and know-how in absence of routine market. Minimize the risks of “build and bust” by careful evaluation of costs (CAPEX and OPEX) is essential
- Development of mRNA vaccines against disease of LMICs importance (e.g. TB, HIV, malaria) can contribute to capacity sustainability and pandemic preparedness
4:00 pm mRNA-Based Therapeutics & Vaccines: Driving a Shift in the Commercial Model
Synopsis
- mRNA technology has potential for faster product design and easier-to-scale manufacturing: how this expands therapeutic and vaccine possibilities
- The potential for speed and scale in development puts pressure on commercial organizations to be more agile, potentially changing the conversation with HCPs and on global equity in healthcare
- Potential evolution of enabling factors that support faster-to-market therapies and vaccines: data generation, digitization, regulatory harmonization, etc
4:30 pm mRNA-Based Vaccines & Delivery of Abs for Global Health Diseases
Synopsis
- Importance of mRNA platform in vaccines for global health diseases for underrepresented populations and countries
- Our portfolio of potential products/vaccines
- Future strategic directions
4:50 pm Achieving Equitable Access to CAR-T & Other Cellular Therapy Through RNA Engineering
Synopsis
- Use of DNA-based cell therapy approaches is limited to academic medical centers in high-income countries due to high costs of manufacturing as well as the level of clinical care needed to manage toxicities
- RNA-engineered cellular therapy is less expensive to manufacture, less complex to prepare and administer and has less potential for significant short and long-term toxicity
- Cartesian Therapeutics has successfully used three different mRNA-engineered cell therapy products in community clinics around the US, as well as in academic centers in a low/medium-income country, demonstrating the potential of RNA to make global distribution of effective clinical therapies more equitable